THE WOODLANDS, Texas--(BUSINESS WIRE)--Dec. 20, 2005--Power3 Medical Products, Inc. (PWRM.PK), a leading proteomics company, today announced that it has filed a provisional patent application with the US Patent and Trademark Office on breast cancer protein biomarkers in blood serum and their use in a test for breast cancer. By monitoring the blood serum concentrations of a group of blood serum proteins and then subjecting the results to biostatistical analysis, scientists at Power3 were able to demonstrate discrimination between three groups of women, women with breast cancer, women with benign breast disease, and normal women with no detectable breast cancer. In addition, some of the biomarkers demonstrated differences between early and late stage disease.
